Projects per year
Personal profile
Headline
FOUNDING CHAIR EMERITUS AND PROFESSOR
Oncological Sciences
Biography
Stuart Aaronson, MD, is the Jack and Jane B. Aron Professor of Neoplastic Diseases; Founding Chair, Emeritus, Department of Oncological Sciences; and Associate Director of Basic and Translational Research at The Tisch Cancer Institute. Dr. Aaronson joined Mount Sinai in 1994 following a long tenure at the National Cancer Institute, during which he was Chief of the Laboratory of Cellular and Molecular Biology.
Dr. Aaronson participated in the discovery of the first normal function of an oncogene and the demonstration that genes encoding growth factors could be transforming (sis/PDGF). He subsequently discovered erbB2 as an erbB-related gene amplified in a primary human breast cancer, and genes for other growth factor signaling molecules activated as oncogenes in human malignancies. Dr. Aaronson’s research has contributed to the development of novel cancer drugs including Herceptin which targets ERBB2, and KGF/FGF7, discovered by him as a unique epithelial cell acting growth factor and which became a drug for treatment of mucositis, a debilitating side effect of certain cancer therapies. His discoveries, including erbB3, PDGFR alpha, and HGF as the ligand for MET, have led to other approved drugs as well as those currently in clinical development as cancer therapeutics. More recently, Dr. Aaronson identified a Wnt autocrine activation mechanism, which helps to drive the malignant phenotype of some human breast, ovary, lung, and soft tissue tumors.
Dr. Aaronson is the recipient of numerous awards including the Distinguished Service Medal from the U.S. Public Health Service, the AACR Award for Outstanding Achievement in Cancer Research, and the Paul Erhlich Prize from Germany. He is the author of more than 485 publications, an inventor on more than 40 patents, and serves on numerous editorial boards and scientific advisory committees. He has trained dozens of investigators, who have gone on to positions in academic medicine or biotech/pharma, or who head cancer centers in this country and abroad.
Fingerprint
- 1 Similar Profiles
Network
-
Tumor Suppressor Signaling Approaches for the Treatment of Metastatic Prostate Cancer
Parsons, R., OZTURK , S., Oh, W., Tewari, A., Aaronson, S. & Rubin, M. R. M. R.
1/01/16 → …
Project: Research
-
Role of Mediators of Wnt-2 Signaling in CRC Development
Gazit, A., Yaniv, A. A. & Aaronson, S.
United States-Israel Binational Science Foundation
1/01/97 → …
Project: Research
-
Equine Infectious Anemia Virus Role of Regulatory Genes inPathogenesis
Gazit, A., Yaniv, A. A., Tronick, S. S. & Aaronson, S.
United States-Israel Binational Science Foundation
1/01/90 → …
Project: Research
-
Transformation and Transposition Activities of MoloneyMurine Sarcoma Virus
Aaronson, S. & Canaani, E. E.
United States-Israel Binational Science Foundation
1/01/80 → …
Project: Research
-
Global DNA methylation of WTC prostate cancer tissues show signature differences compared to non-exposed cases
Yu, H., Tuminello, S., Alpert, N., Van Gerwen, M., Yoo, S., Mulholland, D. J., Aaronson, S. A., Donovan, M., Oh, W. K., Gong, Y., Wang, L., Zhu, J. & Taioli, E., 1 Jun 2022, In: Carcinogenesis. 43, 6, p. 528-537 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation
Esposito, D., Pant, I., Shen, Y., Qiao, R. F., Yang, X., Bai, Y., Jin, J., Poulikakos, P. I. & Aaronson, S. A., Dec 2022, In: Nature Communications. 13, 1, 703.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Wu, X., Yang, X., Xiong, Y., Li, R., Ito, T., Ahmed, T. A., Karoulia, Z., Adamopoulos, C., Wang, H., Wang, L., Xie, L., Liu, J., Ueberheide, B., Aaronson, S. A., Chen, X., Buchanan, S. G., Sellers, W. R., Jin, J. & Poulikakos, P. I., Apr 2021, In: Nature Cancer. 2, 4, p. 429-443 15 p.Research output: Contribution to journal › Article › peer-review
18 Scopus citations -
Exploiting allosteric properties of raf and mek inhibitors to target therapy-resistant tumors driven by oncogenic braf signaling
Adamopoulos, C., Ahmed, T. A., Tucker, M. R., Ung, P. M. U., Xiao, M., Karoulia, Z., Amabile, A., Wu, X., Aaronson, S. A., Ang, C., Rebecca, V. W., Brown, B. D., Schlessinger, A., Herlyn, M., Wang, Q., Shaw, D. E. & Poulikakos, P. I., Jul 2021, In: Cancer Discovery. 11, 7, p. 1716-1735 20 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Scopus citations -
High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer
Rogic, A., Pant, I., Grumolato, L., Fernandez-Rodriguez, R., Edwards, A., Das, S., Sun, A., Yao, S., Qiao, R., Jaffer, S., Sachidanandam, R., Akturk, G., Karlic, R., Skobe, M. & Aaronson, S. A., Dec 2021, In: Nature Communications. 12, 1, 6889.Research output: Contribution to journal › Article › peer-review
Open Access9 Scopus citations
Press / Media
-
US Patent Issued to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI on March 15 for "Methods of treating tumors and cancer, and identifying candidate subjects for such treatment" (New York Inventors)
ALBINO TROILO , Davide Esposito & Stuart Aaronson
16/03/22
1 item of Media coverage
Press/Media
-
US Patent Issued to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI on Feb. 15 for "Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment" (New York Inventors)
ALBINO TROILO & Stuart Aaronson
16/02/22
1 item of Media coverage
Press/Media
-
Mount Sinai Molecular Pathology
Thomas Kraus, Huabao Xiong, David Zhang, Susan Morgello, Jessica Robinson-Papp, Maria Fiel, John Crary, Yasmin Hurd, Stuart Aaronson & Sundar Jagannath
3/10/19
1 item of Media coverage
Press/Media
-
Selective cancer targeting: Hippo, a pathway too big to hide
7/11/17
1 item of Media coverage
Press/Media
-
WIPO PUBLISHES PATENT OF ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI FOR "TREATMENT OF HIPPO PATHWAY MUTANT TUMORS AND METHODS OF IDENTIFYING SUBJECTS AS CANDIDATES FOR TREATMENT" (AMERICAN INVENTORS)
ALBINO TROILO & Stuart Aaronson
6/11/17
1 item of Media coverage
Press/Media